roxadustat + oral iron

Roxadustat + oral iron is a combination therapy used primarily in the treatment of anemia associated with chronic kidney disease (CKD), particularly in elderly or nondialysis-dependent patients. Roxadustat is a **hypoxia-inducible factor prolyl hydroxylase (HIF-PHI) inhibitor** that stimulates erythropoiesis by stabilizing HIF, enhancing endogenous erythropoietin (EPO) production, promoting expression of erythropoietin receptor, suppressing hepcidin expression, and thereby increasing iron bioavailability and hemoglobin synthesis. Oral iron supplements provide an exogenous source of iron to further support hematopoiesis. The combination is shown to improve iron metabolism, anemia indices, and reduce inflammatory markers more effectively than oral iron alone; it also appears to result in fewer adverse effects compared to some other therapies. The combination is primarily indicated for anemia in CKD. Roxadustat was developed as an oral agent, notable for its ability to regulate multiple factors in red blood cell and iron metabolism[1][2].